{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:20Z","timestamp":1791521360411,"version":"4.3.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Children and adolescents with multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) face major treatment challenges. Although newer all-oral regimens have transformed adult TB care, their use in younger populations has largely been extrapolated from adult studies, despite important biologic and clinical differences. Systematic and up-to-date evidence on the effectiveness and safety of contemporary regimens in children and adolescents is lacking. We conducted a global systematic review and meta-analysis to address this gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, EMBASE, Web of Science, Cochrane Library and Google Scholar for studies published between January 1, 2015, and September 1, 2025. Eligible studies included children 0\u201319 years old with confirmed or presumed MDR\/XDR-TB or rifampicin-TB receiving pharmacologic treatment. Outcomes were pooled using a random-effects meta-analysis. The primary outcome was treatment success (cure or completion); severe (grade 3\/4) adverse events were assessed as secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 14 studies comprising 490 children across 13 countries. Overall pooled treatment success was 89% (95% confidence interval: 84%\u201393%;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 51.9%). Newer all-oral regimens achieved slightly higher success (91%) than injectable-containing regimens (83%). Severe grade 3\/4 adverse event were sparse (7 of 14 studies); events occurred in 21% (95% confidence interval: 13%\u201333%), most commonly QT prolongation and anemia, with limited specific drug attribution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Newer, all-oral bedaquiline- and delamanid-based regimens for pediatric MDR\/XDR-TB are effective and generally well tolerated, though the full safety profile remains incompletely characterized. In pediatric MDR\/XDR-TB, where studies are rare, our findings provide the best available evidence and a foundation for improved treatment guidelines and future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005269","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:00:38Z","timestamp":1779336038000},"page":"1003-1012","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Contemporary Drug Regimens for Multidrug- and Extensively Drug-resistant Tuberculosis in Children and Adolescents"],"prefix":"10.1097","volume":"45","author":[{"given":"Wamaka","family":"Kaminyoge","sequence":"first","affiliation":[{"name":"Public Health Programme, Warwick Medical School, University of Warwick, Coventry, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Simfukwe","sequence":"additional","affiliation":[{"name":"Clinical Research Education and Management Services (CREAMS), Queen Elizabeth Central Hospital, Blantyre, Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwiza","family":"Singini","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Sitali","sequence":"additional","affiliation":[{"name":"Doctors Without Borders Germany, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-001X","authenticated-orcid":false,"given":"Felix P.","family":"Chilunga","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-2600(18)30057-2","article-title":"The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the end TB era.","volume":"6","author":"Floyd","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global tuberculosis report 2020\u2014reflections on the global TB burden, treatment and prevention efforts.","volume":"113","author":"Chakaya","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1574-695X.2008.00400.x","article-title":"Extensively drug-resistant tuberculosis: current challenges and threats.","volume":"53","author":"Jain","year":"2008","journal-title":"FEMS Immunol Med Microbiol"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur Respir J"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/ers.09.6","article-title":"MDR-\/XDR-TB management: what it was, current standards and what is ahead.","volume":"3","author":"Monedero","year":"2009","journal-title":"Expert Rev Respir Med"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S2352-4642(24)00330-4","article-title":"Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.","volume":"9","author":"Garcia-Prats","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"R11-20261009","first-page":"e35154","article-title":"Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children: where we stand now.","volume":"15","author":"Chowdhury","year":"2023","journal-title":"Cureus"},{"key":"R12-20261009","first-page":"57","article-title":"Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases: guidelines.","volume":"24","author":"Moore","year":"2009","journal-title":"South Afr J Epidemiol Infect"},{"key":"R13-20261009","first-page":"1","article-title":"The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study.","volume":"17","author":"Golla","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"721817","DOI":"10.3389\/fpubh.2021.721817","article-title":"Drug-resistant tuberculosis among children: a systematic review and meta-analysis.","volume":"9","author":"Song","year":"2021","journal-title":"Front Public Health"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/resp.13143","article-title":"Recent controversies about MDR and XDR\u2010TB: Global implementation of the WHO shorter MDR\u2010TB regimen and bedaquiline for all with MDR\u2010TB?","volume":"23","author":"Dheda","year":"2018","journal-title":"Respirology"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur Respir Rev"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/microorganisms9051074","article-title":"Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in children: the role of bedaquiline and delamanid.","volume":"9","author":"Pecora","year":"2021","journal-title":"Microorganisms"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"2400436","DOI":"10.1183\/13993003.00436-2024","article-title":"Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based non-randomized clinical trial, Kandahar Afghanistan.","volume":"63","author":"Mesic","year":"2024","journal-title":"Eur Respir J"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"e1646","DOI":"10.4081\/monaldi.2021.1646","article-title":"Effectiveness and safety of delamanid-or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: a nationwide study from Belarus, 2015-19.","volume":"91","author":"Solodovnikova","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"e0003754","DOI":"10.1371\/journal.pgph.0003754","article-title":"Treatment outcomes among children and adolescents with extensively drug\u2013resistant (XDR) and pre\u2013XDR tuberculosis: systematic review and meta\u2013analysis.","volume":"5","author":"Patra","year":"2025","journal-title":"PLOS Global Public Health"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14787210.2023.2285917","article-title":"Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug\/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.","volume":"22","author":"Sun","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"14_suppl","key":"R24-20261009","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1200\/jco.2004.22.90140.6098","article-title":"The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials.","volume":"22","author":"Colevas","year":"2004","journal-title":"J Clin Oncol"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane Risk of Bias tool.","volume":"5","author":"Corbett","year":"2014","journal-title":"Res Synth Methods"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.32902\/2663-0338-2023-3-31-35","article-title":"Evaluation of the effectiveness of immunomodulator BI-V in the complex therapy of children and adolescents with multiple drug-resistant pulmonary tuberculosis.","volume":"6","author":"Sakhelashvili-Bil","year":"2023","journal-title":"Infus Chemother"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.eclinm.2020.100290","article-title":"Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.","volume":"20","author":"Mohr-Holland","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.5588\/ijtld.20.0165","article-title":"New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.","volume":"24","author":"Das","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3201\/eid2310.170303","article-title":"Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis.","volume":"23","author":"Achar","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"2002483","DOI":"10.1183\/13993003.02483-2020","article-title":"Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.","volume":"57","author":"Ghosh","year":"2021","journal-title":"Eur Respir J"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"1801154","DOI":"10.1183\/13993003.01154-2018","article-title":"Compassionate use of delamanid in combination with bedaquiline for the treatment of MDR-TB.","volume":"53","author":"Hafkin","year":"2018","journal-title":"Eur Respir J"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"716","DOI":"10.5588\/ijtld.21.0022","article-title":"Bedaquiline for multidrug-resistant TB in paediatric patients.","volume":"25","author":"Moodliar","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"e0214421","DOI":"10.1128\/aac.02144-21","article-title":"Delamanid added to an optimized background regimen in children with multidrug-resistant tuberculosis: results of a phase I\/II clinical trial.","volume":"66","author":"Garcia-Prats","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-20261009","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1183\/13993003.00354-2016","article-title":"Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study.","volume":"48","author":"Smirnova","year":"2016","journal-title":"Eur Respir J"},{"key":"R36-20261009","doi-asserted-by":"crossref","first-page":"100388","DOI":"10.1016\/j.jctube.2023.100388","article-title":"Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil.","volume":"33","author":"Bruzadelli Paulino da Costa","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R37-20261009","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention.","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R38-20261009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"R39-20261009","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability.","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"R40-20261009","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects.","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R41-20261009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1378\/chest.29.3.241","article-title":"The treatment of human pulmonary tuberculosis with cycloserine:* progress report.","volume":"29","author":"Epstein","year":"1956","journal-title":"Dis Chest"},{"key":"R42-20261009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1568026033452537","article-title":"Fluoroquinolones: action and resistance.","volume":"3","author":"Drlica","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"R43-20261009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2352-4642(21)00003-1","article-title":"Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic.","volume":"5","author":"Mohr-Holland","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R44-20261009","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3390\/molecules22122267","article-title":"Amikacin: uses, resistance, and prospects for inhibition.","volume":"22","author":"Ramirez","year":"2017","journal-title":"Molecules"},{"key":"R45-20261009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nsmb.1755","article-title":"The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.","volume":"17","author":"Stanley","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"R46-20261009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/ija.ija_1187_24","article-title":"Individual participant data (IPD) meta-analysis: an introduction\u2013narrative review.","volume":"69","author":"Rai","year":"2025","journal-title":"Indian J Anaesth"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:02:37Z","timestamp":1791518557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005269"}},"subtitle":["A Global Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005269","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"2026-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}